KR20230146047A - 메타뉴모바이러스에 결합하는 항체, 항원성 메타뉴모바이러스 단백질, 및 그의 용도 - Google Patents

메타뉴모바이러스에 결합하는 항체, 항원성 메타뉴모바이러스 단백질, 및 그의 용도 Download PDF

Info

Publication number
KR20230146047A
KR20230146047A KR1020237030905A KR20237030905A KR20230146047A KR 20230146047 A KR20230146047 A KR 20230146047A KR 1020237030905 A KR1020237030905 A KR 1020237030905A KR 20237030905 A KR20237030905 A KR 20237030905A KR 20230146047 A KR20230146047 A KR 20230146047A
Authority
KR
South Korea
Prior art keywords
seq
amino acid
variable region
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237030905A
Other languages
English (en)
Korean (ko)
Inventor
지펭 첸
카라 에스. 콕스
아서 프리드만
제니퍼 다운 갈리
후아-푸 수
에이민 탕
칼피트 보라
지윤 웬
샤오 샤오
란 장
Original Assignee
머크 샤프 앤드 돔 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 머크 샤프 앤드 돔 엘엘씨 filed Critical 머크 샤프 앤드 돔 엘엘씨
Publication of KR20230146047A publication Critical patent/KR20230146047A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/1027—
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020237030905A 2021-02-12 2022-02-08 메타뉴모바이러스에 결합하는 항체, 항원성 메타뉴모바이러스 단백질, 및 그의 용도 Pending KR20230146047A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163148920P 2021-02-12 2021-02-12
US63/148,920 2021-02-12
US202163276172P 2021-11-05 2021-11-05
US63/276,172 2021-11-05
PCT/US2022/015565 WO2022173714A2 (en) 2021-02-12 2022-02-08 Antibodies that bind metapneumovirus, antigenic metapneumovirus proteins, and uses thereof

Publications (1)

Publication Number Publication Date
KR20230146047A true KR20230146047A (ko) 2023-10-18

Family

ID=82838690

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237030905A Pending KR20230146047A (ko) 2021-02-12 2022-02-08 메타뉴모바이러스에 결합하는 항체, 항원성 메타뉴모바이러스 단백질, 및 그의 용도

Country Status (9)

Country Link
US (1) US20240327502A1 (enExample)
EP (1) EP4291232A4 (enExample)
JP (1) JP2024512215A (enExample)
KR (1) KR20230146047A (enExample)
AU (1) AU2022220616A1 (enExample)
BR (1) BR112023016241A2 (enExample)
CA (1) CA3208018A1 (enExample)
MX (1) MX2023009447A (enExample)
WO (1) WO2022173714A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025038512A1 (en) * 2023-08-17 2025-02-20 Merck Sharp & Dohme Llc Methods for detecting pcr chimeras
WO2025097674A1 (zh) * 2023-11-08 2025-05-15 安炎达医药技术(广州)有限公司 一种新型pace4抑制剂及其在抗骨关节炎中的应用
CN119143871B (zh) * 2024-11-20 2025-02-07 首都儿科研究所 用于人偏肺病毒检测的单克隆抗体、检测试剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096451A1 (en) * 2002-07-25 2004-05-20 Young James F. Methods of treating and preventing RSV, hMPV, and PIV using anti-RSV, anti-hMPV, and anti-PIV antibodies
US7438907B2 (en) * 2002-11-15 2008-10-21 Genmab A/S Human monoclonal antibodies against CD25
JP2010505876A (ja) * 2006-10-04 2010-02-25 ザ スクリプス リサーチ インスティテュート ヒトメタニューモウイルスを中和するヒト抗体
JP5642972B2 (ja) * 2007-02-21 2014-12-17 ユニバーシティー オブ マサチューセッツＵｎｉｖｅｒｓｉｔｙ ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ Ｃ型肝炎ウイルス（ｈｃｖ）に対するヒト抗体およびその使用
EP2445527A2 (en) * 2009-06-24 2012-05-02 ID Biomedical Corporation of Quebec Vaccine
KR101815265B1 (ko) * 2013-06-20 2018-01-04 한올바이오파마주식회사 FcRn 특이적 인간 항체 및 이를 포함하는 자가면역 질환 치료용 조성물
CA3138550A1 (en) * 2019-04-30 2020-11-05 Target Discovery Merger Sub II, LLC Cancer associated antibody compositions and methods of use

Also Published As

Publication number Publication date
WO2022173714A3 (en) 2022-11-10
BR112023016241A2 (pt) 2023-11-14
AU2022220616A1 (en) 2023-08-31
WO2022173714A2 (en) 2022-08-18
EP4291232A2 (en) 2023-12-20
EP4291232A4 (en) 2025-04-02
US20240327502A1 (en) 2024-10-03
CA3208018A1 (en) 2022-08-18
MX2023009447A (es) 2023-10-06
JP2024512215A (ja) 2024-03-19

Similar Documents

Publication Publication Date Title
AU2020286284B2 (en) Novel anti-CD39 antibodies
EP2970435B1 (en) Methods for producing fabs and bi-specific antibodies
KR101877109B1 (ko) 항-il-17a 항체 및 자가면역 및 염증성 장애의 치료에서의 그의 용도
DK2734545T3 (en) NEUTRALIZING ANTI-INFLUENZA A VIRUS ANTIBODIES AND APPLICATIONS THEREOF
US20250145690A1 (en) Human monoclonal antibodies that broadly target coronaviruses
CN107921122A (zh) 与cd38结合的抗体治疗剂
CN113164780A (zh) 抗lap抗体变体及其用途
US20240327502A1 (en) Antibodies that bind metapneumovirus, antigenic metapneumovirus proteins, and uses thereof
JP2024509054A (ja) 抗体
CN110799538B (zh) 抗cd3抗体及其制备和使用方法
JP7717194B2 (ja) 呼吸器合胞体ウイルスに対する抗体及びその使用
EP4230650B1 (en) Antibodies capable of binding to the spike protein of coronavirus sars-cov-2
US12559544B2 (en) Antibodies that bind human metapneumovirus fusion protein and their use
KR20240142594A (ko) 코로나바이러스 sars-cov-2의 스파이크 단백질에 결합할 수 있는 항체
US12612449B2 (en) HIV-1 antibodies
KR20220119467A (ko) 이중특이적 fcyriii x cd30 항체 작제물의 제조 방법
CN117769567A (zh) 结合偏肺病毒的抗体、抗原性偏肺病毒蛋白及其用途
WO2024068996A1 (en) Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
WO2023172881A1 (en) Hmpv antibodies and their use
HK1253584B (zh) 与cd38结合的抗体治疗剂

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000